Table: Aska Pharmaceutical Holdings -2023/24 group results

ASKA Pharmaceutical Holdings

10/05/2024 07:00

May 10 (Reuters)- 
          Aska Pharmaceutical Holdings Co., Ltd. 
          CONSOLIDATED FINANCIAL HIGHLIGHTS 
     (in billions of yen unless specified)
                 Year ended      Year ended       Year to       NEXT   
              Mar 31, 2024    Mar 31, 2023   Mar 31, 2025     YEAR     
                 LATEST         YEAR-AGO        COMPANY      COMPANY   
                 RESULTS         RESULTS       FORECAST    H1 FORECAST 
  Sales           62.84           60.46          63.00                 
               (+3.9 pct)      (+6.8 pct)     (+0.2 pct)               
  Operating        6.50            5.11           6.70                 
               (+27.3 pct)     (+6.5 pct)     (+3.1 pct)               
  Recurring        6.52            5.23           6.70                 
               (+24.6 pct)     (+7.2 pct)     (+2.7 pct)               
  Net
  Net              7.55            4.24           5.00                 
               (+78.0 pct)     (-1.2 pct)     (-33.7 pct)              
  EPS          266.51 yen      150.08 yen     176.50 yen               
  Ann Div       40.00 yen       16.00 yen      50.00 yen               
  -Q2 Div       20.00 yen       8.00 yen       25.00 yen               
  -Q4 Div       20.00 yen       8.00 yen       25.00 yen               
  
  NOTE - Aska Pharmaceutical Holdings Co., Ltd..
  *Second Net profit row denotes profit attributable to owners ofthe parent 
  To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4886.T